Scientists test drug duo to outsmart resistant lung cancer
NCT ID NCT03133546
Summary
This study tested whether adding the drug bevacizumab to standard treatment (osimertinib) could better control advanced non-small cell lung cancer that had developed a specific resistance mutation. It involved 155 adults whose cancer had progressed after initial targeted therapy. The goal was to see if the combination could slow cancer growth longer than the single drug alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
-
Fund. Jimenez Diaz
Madrid, Spain
-
Geneva University Hospital (HUG)
Geneva, Switzerland
-
Hospital Arnau de Vilanova
Valencia, Spain
-
Hospital General Alicante
Alicante, Spain
-
Hospital General de Valencia
Valencia, Spain
-
Hospital Puerta de Hierro
Madrid, Spain
-
Hospital Sant Pau
Barcelona, Spain
-
Hospital Teresa Herrara
A Coruña, Spain
-
Hospital Virgen del Rocio
Seville, Spain
-
Hospital de la Princesa
Madrid, Spain
-
Hospital la Paz
Madrid, Spain
-
ICO Badalona
Barcelona, Spain
-
ICO Hospitalet
Barcelona, Spain
-
Kantonsspital St. Gallen
Sankt Gallen, Switzerland
-
Kantonsspital Winterthur
Winterthur, Switzerland
-
Mid Western Cancer Centre
Limerick, Ireland
-
National Cancer Centre
Goyang, South Korea
-
National University Hospital
Singapore, Singapore
-
OSI Bilbao Basurto
Bilbao, Spain
-
Severance Hospital, Yonsei University Health System
Seoul, South Korea
-
St. James Hospital
Dublin, Ireland
-
Tan Tock Seng Hospital
Singapore, Singapore
-
UniversitatSpital Zurich
Zurich, Switzerland
-
VU University Medical Centre
Amsterdam, Netherlands
Conditions
Explore the condition pages connected to this study.